US equities |
NVDA $239.24 ▲+0.14% MU $1,045.56 ▼-1.73% SPCX $171.92 ▲+0.49% AMD $649.42 ▲+2.80% MRVL $287.01 ▲+5.81% AVGO $375.81 ▲+3.67% INTC $112.50 ▼-3.18% MSFT $529.30 ▲+0.78%
FinancialContent

Cellectar Biosciences, Inc. - Common Stock (NQ:CLRB)

1.510 -0.160 (-9.58%)
Delayed Quote Updated: 4:00 PM EDT, Oct 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cellectar Biosciences, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
Cellectar and Evestia Clinical Announce Partnership to Support Auger-Emitting Radiopharmaceutical Clinical Trial in Triple-Negative Breast Cancer (TNBC)
Intends to Initiate Phase 1b Clinical Trial in TNBC at Mayo Clinic in Fourth Quarter 2025 
From Cellectar Biosciences, Inc.
Via GlobeNewswire
News headline image
Cellectar Biosciences and ITM Enter Supply Agreement for GMP-Grade Actinium-225
Supports Clinical Development of CLR 121225, Actinium-Labeled Compound for the Treatment of Solid Tumors 
From Cellectar Biosciences, Inc.
Via GlobeNewswire
News headline image
Earnings Scheduled For August 14, 2025 ↗
 
Via Benzinga
News headline image
A Peek at Cellectar Biosciences's Future Earnings ↗
 
Via Benzinga
News headline image
Cellectar Biosciences to Participate at Oppenheimer 3rd Annual Targeted Radiopharmaceutical Therapies in Oncology Summit
From Cellectar Biosciences, Inc.
Via GlobeNewswire
News headline image
Cellectar Biosciences to Participate in Multiple Upcoming Medical Meetings and Industry Conferences in September
From Cellectar Biosciences, Inc.
Via GlobeNewswire
News headline image
Cellectar Biosciences to Present Data in Poster Presentation at the American Association for Cancer Research Special Conference on Advances in Pancreatic Cancer Research
From Cellectar Biosciences, Inc.
Via GlobeNewswire
News headline image
Cellectar Biosciences to Present Data in Oral Session and Panel Discussions at the American Association for Cancer Research Special Conference on Discovery and Innovation in Pediatric Cancer
Presenting Data from CLOVER-2 Phase 1 Clinical Study Evaluating Iopofosine I 131 in Relapsed/Refractory Pediatric High-Grade Glioma (r/r pHGG) Patients 
From Cellectar Biosciences, Inc.
Via GlobeNewswire
News headline image
Cellectar Cuts Q2 Losses and Expenses ↗
Via The Motley Fool
News headline image
Cellectar Biosciences Reports Second Quarter 2025 Financial Results and Provides a Corporate Update
From Cellectar Biosciences, Inc.
Via GlobeNewswire
News headline image
Cellectar Biosciences to Report Second Quarter Financial Results and Host a Conference Call on Thursday, August 14, 2025
From Cellectar Biosciences, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Cellectar Biosciences Announces Closing of $6.9 Million Underwritten Public Offering, including Full Exercise of Over-Allotment Option
From Cellectar Biosciences, Inc.
Via GlobeNewswire
News headline image
Which stocks are moving on Tuesday? ↗
Keep an eye on the top gainers and losers in Tuesday's session, as they reflect the most notable price movements. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
Which stocks are experiencing notable movement on Tuesday? ↗
Intrigued by the market activity in the middle of the day on Tuesday? Uncover the key winners and losers of today's session in our insightful analysis. 
Via Chartmill
News headline image
Let's uncover which stocks are experiencing notable gaps during today's session. ↗
Today's session on Tuesday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session. 
Via Chartmill
News headline image
Cellectar Biosciences Announces Pricing of $6 Million Underwritten Public Offering
From Cellectar Biosciences, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
 
Via Benzinga
News headline image
Cellectar Biosciences and U.S.-based Nusano Enter Into Multi-Isotope Supply Agreement
From Cellectar Biosciences, Inc.
Via GlobeNewswire
News headline image
Cellectar Biosciences Submits Phase 1b Clinical Trial Protocol to US Food and Drug Administration for CLR 125 to Treat Triple-Negative Breast Cancer (TNBC)
From Cellectar Biosciences, Inc.
Via GlobeNewswire
News headline image
Why Cheetah Mobile Shares Are Trading Higher By Over 11%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Top movers in Wednesday's after hours session ↗
After the conclusion of the US market's regular session on Wednesday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers. 
Via Chartmill
News headline image
Cellectar Biosciences Announces One-for-Thirty Reverse Stock Split
From Cellectar Biosciences, Inc.
Via GlobeNewswire
News headline image
Cellectar Biosciences Provides Update on CLOVER-2 Phase 1 Clinical Trial of Iopofosine I 131 in Pediatric Patients with Relapsed/Refractory High-Grade Glioma
In Patients Receiving a Minimum of 55 mCi an Average 5.4 Months of PFS was Observed: Twice the Reported 2.25 Median 
From Cellectar Biosciences, Inc.
Via GlobeNewswire
News headline image
The trading volume of these stocks is deviating from the norm in today's session. ↗
Let's have a look at what is happening on the US markets on Thursday. Below you can find the stocks with an unusual volume in today's session. 
Via Chartmill
News headline image
Which stocks are gapping on Thursday? ↗
Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Thursday. Let's explore the market movements and identify the stocks with significant gaps. 
Via Chartmill
News headline image
Cellectar Biosciences Enters into Common Stock Agreements to Raise $2.5 Million Priced at Market Under Nasdaq Rules
From Cellectar Biosciences, Inc.
Via GlobeNewswire
News headline image
Synergy CHC Corp. (NASDAQ: SNYR) Restructures Debt with $20M Facility to Power Global Growth and FOCUSfactor Beverage Expansion
Via AB Newswire
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >